From the Department of Translational Medical Science, Section of Pediatrics, University of Naples "Federico II", Naples, Italy.
the Department of Woman, Child and General and Specialized Surgery, Second University of Naples, Naples, Italy.
J Pediatr Gastroenterol Nutr. 2022 Nov 1;75(5):595-600. doi: 10.1097/MPG.0000000000003576. Epub 2022 Jul 28.
The aims of our study were to evaluate health-related quality of life (HRQoL) in children affected by inflammatory bowel disease (IBD) during the first wave of Coronavirus disease 2019 (COVID-19) pandemic and after 12 months.
This was a single-center, prospective, observational study conducted between April 2020 and April 2021. Children from 10 to 18 years with a confirmed diagnosis of IBD were enrolled during the first COVID-19-related national quarantine. The following information was collected at the baseline and after 12 months: IBD subtype, location and phenotype, disease activity, current and previous therapies. Patients were asked to complete the PROMIS Anxiety and IMPACT III questionnaires.
One hundred and eighteen patients were enrolled, of whom 54 (46%) were affected by Crohn disease (CD) and 64 (54%) with ulcerative colitis (UC; median age: 15.5 years, range 10.3-18; M/F: 68/50). Median HRQoL was significantly decreased after 12 months compared with the beginning of COVID-19-related quarantine (T1: 76.7 vs T2: 72.8; P < 0.001). At 12 months, a higher number of children were reported to be in active disease when compared with the enrollment [T2: 22/108 (20.4%) vs T1: 12/118 (10%); P = 0.02]. Multivariate analysis showed a significant influence on HRQoL of quarantine period ( P < 0.001), female sex ( P = 0.016), biologic therapy ( P = 0.011), and active disease ( P < 0.001).
A deterioration of HRQoL after 12 months from COVID-19-related quarantine was observed. Additionally, the higher number of children with active disease at 12 months compared with enrollment may suggest detrimental consequences of the reduced disease control, contributing to decreased HRQoL.
本研究旨在评估儿童炎症性肠病（IBD）患者在首次新冠肺炎（COVID-19）大流行期间和 12 个月后的健康相关生活质量（HRQoL）。
这是一项单中心、前瞻性、观察性研究，于 2020 年 4 月至 2021 年 4 月期间进行。在第一次 COVID-19 相关国家封锁期间，招募了 10 至 18 岁确诊为 IBD 的儿童。在基线和 12 个月后收集了以下信息：IBD 亚型、位置和表型、疾病活动度、当前和既往治疗。患者被要求完成 PROMIS 焦虑和 IMPACT III 问卷。
共纳入 118 例患者，其中 54 例（46%）患有克罗恩病（CD），64 例（54%）患有溃疡性结肠炎（UC；中位年龄 15.5 岁，范围 10.3-18；男/女：68/50）。与 COVID-19 相关隔离开始时相比，12 个月后的 HRQoL 显著下降（T1：76.7 vs T2：72.8；P<0.001）。在 12 个月时，与入组时相比，报告更多的儿童处于活动期疾病[T2：22/108（20.4%）vs T1：12/118（10%）；P=0.02]。多变量分析显示，隔离期（P<0.001）、女性（P=0.016）、生物治疗（P=0.011）和活动期疾病（P<0.001）对 HRQoL 有显著影响。
从 COVID-19 相关隔离开始 12 个月后，观察到 HRQoL 恶化。此外，与入组时相比，12 个月时处于活动期疾病的儿童数量较多，这可能表明疾病控制的降低会产生不利影响，导致 HRQoL 下降。
